Big News: Wegovy® Now Approved to Treat Fatty Liver Disease (MASH)
We’re excited to share some important news from the FDA that may impact many of our patients. On August 15, 2025, the glp-1-surgery-safety-new-fasting-rules-for-zepbound-wegovy”>wegovy-and-zepbound“>wegovy-approved-by-fda-for-the-treatment-of-adults-with-noncirrhotic-mash“>mash-with-zepbound-to-advanced-zepboundbrosis-302531394.html” target=”_blank” rel=”noopener noreferrer nofollow”>FDA approved a new use for Wegovy® (tirzepatide-glp1-nutrition-weight-loss”>semaglutide–glp-1/zepbound-now-available-through-lillydirect-a-new-option-for-tirzepatide-access-at-a-presemaglutideice”>tirzepatide-glp1-nutrition-weight-loss”>semaglutide 2.4 mg injection)—already well known for…
